New RSV vaccine trial aims to protect vulnerable adults in japan

NCT ID NCT07543380

NEW Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen May 09, 2026 · Last updated May 09, 2026

Summary

This study tests an experimental RSV vaccine in 130 adults aged 18 to 59 in Japan who have health conditions like chronic lung or heart disease that make them more likely to get very sick from RSV. The vaccine is designed to help the body build defenses against the virus. Researchers will check how well the vaccine works and monitor for side effects over about 2 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fukuwa Clinic

    Chuo-ku, Tokyo, 104-0031, Japan

  • Nihonbashi Sakura Clinic

    Chuo-ku, Tokyo, 103-0025, Japan

  • Tenjin Sogo Clinic

    Fukuoka, 810-0021, Japan

  • Tokyo-Eki Center-building Clinic

    Chuo-ku, Tokyo, 103-0027, Japan

  • Tsuchiura Beryl Clinic

    Tsuchiura, Ibaraki, 300-0062, Japan

Conditions

Explore the condition pages connected to this study.